NASDAQ:IART

Integra LifeSciences (IART) Stock Forecast, Price & News

$38.05

-0.26 (-0.68%)

(As of 09/26/2023 ET)

Compare

Today's Range: $37.93
▼
$38.53
50-Day Range: $38.05
▼
$45.97
52-Week Range: $37.36
▼
$60.69

Volume: 710,888 shs
Average Volume: 586,214 shs
Market Capitalization: $3.10 billion

P/E Ratio: 24.24
Dividend Yield: N/A
Price Target: $47.29

Integra LifeSciences MarketRank™ Forecast

Analyst Rating: Reduce
1.86 Rating Score
Upside/Downside: 24.3% Upside
$47.29 Price Target
Short Interest: Healthy
3.64% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.50
Upright™ Environmental Score
News Sentiment: 0.47
Based on 6 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 11.15%
From $3.14 to $3.49 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.34 out of 5 stars

Medical Sector

263rd out of 963 stocks

Surgical & Medical Instruments Industry

32nd out of 98 stocks

1.9

Analyst's Opinion

Consensus Rating
Integra LifeSciences has received a consensus rating of Reduce. The company's average rating score is 1.86, and is based on 2 buy ratings, 2 hold ratings, and 3 sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $47.29, Integra LifeSciences has a forecasted upside of 24.3% from its current price of $38.05.
Amount of Analyst Coverage
Integra LifeSciences has only been the subject of 3 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
3.64% of the float of Integra LifeSciences has been sold short.
Short Interest Ratio / Days to Cover
Integra LifeSciences has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Integra LifeSciences has recently decreased by 9.19%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Integra LifeSciences does not currently pay a dividend.
Dividend Growth
Integra LifeSciences does not have a long track record of dividend growth.

4.0

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Integra LifeSciences has received a 54.98% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Wound dressings", "Medical monitors", and "Sinus surgery instruments" products. See details.
Environmental Sustainability
The Environmental Impact score for Integra LifeSciences is -1.50.

1.9

News and Social Media Coverage

News Sentiment
Integra LifeSciences has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Integra LifeSciences this week, compared to 4 articles on an average week.
Search Interest
Only 1 people have searched for IART on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Integra LifeSciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Integra LifeSciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.90% of the stock of Integra LifeSciences is held by insiders.
Percentage Held by Institutions
84.13% of the stock of Integra LifeSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5

Earnings and Valuation

Earnings Growth
Earnings for Integra LifeSciences are expected to grow by 11.15% in the coming year, from $3.14 to $3.49 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Integra LifeSciences is 24.24, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 116.76.
Price to Earnings Ratio vs. Sector
The P/E ratio of Integra LifeSciences is 24.24, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 109.83.
Price to Earnings Growth Ratio
Integra LifeSciences has a PEG Ratio of 1.55. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Integra LifeSciences has a P/B Ratio of 1.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Integra LifeSciences (NASDAQ:IART) Stock

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

IART Price History

30 days | 90 days | 365 days | Advanced Chart

IART Stock News Headlines

September 21, 2023 | tmcnet.com

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Integra LifeSciences Holdings Corporation (IART)

September 21, 2023 | businesswire.com

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Integra LifeSciences Holdings Corporation (IART)

September 27, 2023 | Wall Street Fundamentals (Ad)

The "Plug and Play" Model Putting Online Giants to Shame

While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."

September 21, 2023 | benzinga.com

FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Integra LifeSciences Holdings Corporation - IART

September 18, 2023 | businesswire.com

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Integra LifeSciences Holdings Corporation Investors

September 16, 2023 | prnewswire.com

INTEGRA DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Integra To Contact Him Directly To Discuss Their Options

September 15, 2023 | technews.tmcnet.com

Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Integra LifeSciences Holdings Corporation (IART) Investors

September 14, 2023 | benzinga.com

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Integra Lifesciences Holdings Corporation (IART)

September 27, 2023 | Wall Street Fundamentals (Ad)

The "Plug and Play" Model Putting Online Giants to Shame

September 14, 2023 | businesswire.com

ROSEN, A LEADING LAW FIRM, Encourages Integra LifeSciences Holdings Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in ...

September 13, 2023 | businesswire.com

INTEGRA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Integra LifeSciences Holdings Corp. and Encourages Investors to Contact the Firm

September 13, 2023 | businesswire.com

Shareholder Alert: Robbins LLP Informs Shareholders of Class Action Filed Against Integra Lifesciences Holdings Corporation (IART)

September 13, 2023 | finance.yahoo.com

Integra LifeSciences Holdings (NASDAQ:IART) Has Some Way To Go To Become A Multi-Bagger

September 8, 2023 | finance.yahoo.com

Integra Lifesciences Holdings (IART): A Hidden Gem or a Mirage? Unearthing Its True Market Value

August 30, 2023 | finance.yahoo.com

Integra LifeSciences Holdings Corporation (NASDAQ:IART) Shares Could Be 38% Below Their Intrinsic Value Estimate

August 25, 2023 | finance.yahoo.com

Integra (IART) CSS Sales Aid, Boston Recall Hurts Growth

August 25, 2023 | finance.yahoo.com

Why Is Integra (IART) Down 7.9% Since Last Earnings Report?

August 24, 2023 | msn.com

Morgan Stanley Downgrades Integra Lifesciences Holdings (IART)

August 18, 2023 | seekingalpha.com

Integra LifeSciences: Uncertainties To Intrinsic Value Remain, Reiterate Hold

August 10, 2023 | finance.yahoo.com

18 Highest Paying Countries for Neurosurgeons

August 10, 2023 | seekingalpha.com

Integra LifeSciences Holdings Corporation 2023 Q2 - Results - Earnings Call Presentation

August 8, 2023 | finance.yahoo.com

Pleasing Signs As A Number Of Insiders Buy Integra LifeSciences Holdings Stock

August 1, 2023 | markets.businessinsider.com

Truist Financial Sticks to Its Hold Rating for Integra Lifesciences (IART)

July 28, 2023 | finance.yahoo.com

Integra's (IART) Q2 Earnings Top Estimates, 2023 View Cut

July 28, 2023 | markets.businessinsider.com

Integra Lifesciences (IART) Receives a Buy from JMP Securities

July 27, 2023 | markets.businessinsider.com

Integra LifeSciences Q2 Earnings Fall; Cuts Annual Outlook; Plans $125 Mln Share Buyback

July 27, 2023 | finanznachrichten.de

Integra LifeSciences Holdings Corporation: Integra LifeSciences Reports Second Quarter 2023 Financial Results

See More Headlines

Receive IART Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Integra LifeSciences and its competitors with MarketBeat's FREE daily newsletter.

IART Company Calendar

Last Earnings: 7/26/2023
Today: 9/27/2023
Next Earnings (Estimated): 10/25/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: Health Care Equipment
Sector: Medical
Current Symbol: NASDAQ:IART
CUSIP: 45798520
CIK: 917520
Web: www.integralife.com
Phone: (609) 275-0500
Fax: 609-750-4277
Employees: 3,722
Year Founded: 1989

Price Target and Rating

Average Stock Price Forecast: $47.29
High Stock Price Forecast: $60.00
Low Stock Price Forecast: $39.00
Forecasted Upside/Downside: +24.3%
Consensus Rating: Reduce
Rating Score (0-4): 1.86
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): $1.57
Trailing P/E Ratio: 24.24
Forward P/E Ratio: 12.12
P/E Growth: 1.56
Net Income: $180.55 million
Net Margins: 8.49%
Pretax Margin: 10.13%
Return on Equity: 15.60%
Return on Assets: 7.06%

Debt

Debt-to-Equity Ratio: 0.79
Current Ratio: 2.78
Quick Ratio: 1.85

Sales & Book Value

Annual Sales: $1.56 billion
Price / Sales: 1.99
Cash Flow: $4.79 per share
Price / Cash Flow: 7.94
Book Value: $21.57 per share
Price / Book: 1.76

Miscellaneous

Outstanding Shares: 81,400,000
Free Float: 79,039,000
Market Cap: $3.10 billion
Optionable: Optionable
Beta: 1.20

Social Links

The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Mr. Jan De Witte (Age 59)
Pres, CEO & Director
Comp: $1.82M

Mr. Eric Ian Schwartz (Age 54)
Exec. VP, Chief Legal Officer & Sec.
Comp: $847.2k

Mr. Robert T. Davis Jr. (Age 64)
Exec. VP & Pres of Tissue Technologies
Comp: $781.23k

Mr. Michael J. McBreen (Age 57)
Exec. VP & Pres of Codman Specialty Surgical
Comp: $780.77k

Ms. Lea Daniels Knight
Exec. VP & CFO

Mr. Stephen Leonard (Age 61)
Corp. VP of Global Operations & Supply Chain

Mr. Jeffrey A. Mosebrook (Age 47)
Sr. VP & PAO

Mr. Mathieu Aussermeier
VP of Corp. Fin., Investor Relations & Treasurer

Dr. Kenneth E. Burhop Ph.D. (Age 69)
Corp. VP & Chief Scientific Officer

Mr. William Compton
Chief Information Officer & Corp. VP

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

IART Stock - Frequently Asked Questions

Should I buy or sell Integra LifeSciences stock right now?: 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Integra LifeSciences in the last twelve months. There are currently 3 sell ratings, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "reduce" IART shares.
View IART analyst ratings or view top-rated stocks.
What is Integra LifeSciences' stock price forecast for 2023?: 7 Wall Street analysts have issued 1 year target prices for Integra LifeSciences' shares. Their IART share price forecasts range from $39.00 to $60.00. On average, they expect the company's stock price to reach $47.29 in the next year. This suggests a possible upside of 24.3% from the stock's current price.
View analysts price targets for IART or view top-rated stocks among Wall Street analysts.
How have IART shares performed in 2023?: Integra LifeSciences' stock was trading at $56.07 at the beginning of the year. Since then, IART shares have decreased by 32.1% and is now trading at $38.05.
View the best growth stocks for 2023 here.
When is Integra LifeSciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, October 25th 2023.
View our IART earnings forecast.
How were Integra LifeSciences' earnings last quarter?: Integra LifeSciences Holdings Co. (NASDAQ:IART) released its quarterly earnings results on Wednesday, July, 26th. The life sciences company reported $0.71 EPS for the quarter, topping analysts' consensus estimates of $0.57 by $0.14. The life sciences company had revenue of $381.30 million for the quarter, compared to analysts' expectations of $388.79 million. Integra LifeSciences had a trailing twelve-month return on equity of 15.60% and a net margin of 8.49%. The firm's revenue was down 4.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.82 EPS.
What ETFs hold Integra LifeSciences' stock?: ETFs with the largest weight of Integra LifeSciences (NASDAQ:IART) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Fidelity Digital Health ETF (FDHT), ROBO Global Healthcare Technology and Innovation ETF (HTEC), First Trust Health Care AlphaDEX Fund (FXH), SPDR S&P Health Care Equipment ETF (XHE), WisdomTree U.S. AI Enhanced Value Fund (AIVL) and Invesco Nasdaq Future Gen 200 ETF (QQQS).iShares U.S. Medical Devices ETF (IHI).
When did Integra LifeSciences' stock split?: Integra LifeSciences's stock split on Tuesday, January 3rd 2017. The 2-1 split was announced on Thursday, December 22nd 2016. The newly issued shares were distributed to shareholders after the closing bell on Wednesday, December 21st 2016. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.
What guidance has Integra LifeSciences issued on next quarter's earnings?: Integra LifeSciences issued an update on its FY 2023 earnings guidance on Thursday, July, 27th. The company provided earnings per share guidance of $3.10-$3.18 for the period, compared to the consensus earnings per share estimate of $3.12. The company issued revenue guidance of $1.55 billion-$1.56 billion, compared to the consensus revenue estimate of $1.56 billion.

What is Peter J. Arduini's approval rating as Integra LifeSciences' CEO?: 173 employees have rated Integra LifeSciences Chief Executive Officer Peter J. Arduini on Glassdoor.com. Peter J. Arduini has an approval rating of 74% among the company's employees.
What other stocks do shareholders of Integra LifeSciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Integra LifeSciences investors own include Boeing (BA), NVIDIA (NVDA), AbbVie (ABBV), Adobe (ADBE), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Intel (INTC), Marvell Technology (MRVL), Alexion Pharmaceuticals (ALXN) and Abbott Laboratories (ABT).
What is Integra LifeSciences' stock symbol?: Integra LifeSciences trades on the NASDAQ under the ticker symbol "IART."
Who are Integra LifeSciences' major shareholders?: Integra LifeSciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Shaolin Capital Management LLC (0.00%), Champlain Investment Partners LLC (4.79%), Capital Research Global Investors (4.00%), Alliancebernstein L.P. (3.53%), Clearbridge Investments LLC (3.39%) and Cooke & Bieler LP (3.37%). Insiders that own company stock include Eric Schwartz, Glenn Coleman, Jeffrey Mosebrook, Lisa Evoli, Michael J Mcbreen, Raymond G Murphy, Stuart Essig, Tru St Partnership, LP and Witte Jan De.
View institutional ownership trends.
How do I buy shares of Integra LifeSciences?: Shares of IART stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Integra LifeSciences' stock price today?: One share of IART stock can currently be purchased for approximately $38.05.
How much money does Integra LifeSciences make?: Integra LifeSciences (NASDAQ:IART) has a market capitalization of $3.10 billion and generates $1.56 billion in revenue each year. The life sciences company earns $180.55 million in net income (profit) each year or $1.57 on an earnings per share basis.
How many employees does Integra LifeSciences have?: The company employs 3,722 workers across the globe.
Does Integra LifeSciences have any subsidiaries?: The following companies are subsidiares of Integra LifeSciences: ACell Inc, ACell Inc., Arkis BioSciences, Arkis Biosciences Inc., Ascension Orthopedics Inc., Ascension Orthopedics Limited, BIMECO Inc., BioD LLC, BioDlogics LLC, BioRecovery LLC, CardioDyne Inc., Cathtec Incorporated, Caveangle Limited, Codman Neuro, Confluent Surgical, Confluent Surgical Inc., Derma First Aid Products Inc., Derma Sciences, Derma Sciences Canada Inc., Derma Sciences Europe Limited, Derma Sciences Inc., EndoSolutions Inc., Fiber Imaging Technologies Inc., GMS Gesellschaft für medizinische Sondentechnik mbH, ILS Financing (Ireland) Limited, ILS Financing Corporation, ILS Services Switzerland Ltd., ILS Surgical Investments LLC, INS Sweden AB, Integra Burlington MA Inc., Integra CI Inc., Integra Canada ULC, Integra Euro Holdings Inc., Integra France Holdings SAS, Integra German Holdings GmbH, Integra GmbH, Integra Japan K.K., Integra LS (Benelux) NV, Integra LS Mexico S. DE R. L. DE C.V., Integra LifeSciences (Canada) Holdings Inc., Integra LifeSciences (Ireland) Limited, Integra LifeSciences (Shanghai) Co. Ltd., Integra LifeSciences Austria GmbH, Integra LifeSciences Brazil Ltda., Integra LifeSciences Corporation, Integra LifeSciences Enterprises LLLP, Integra LifeSciences Financing (Cyprus) Limited, Integra LifeSciences Italy S.r.l., Integra LifeSciences Middle East FZ-LLC, Integra LifeSciences Production Corporation, Integra LifeSciences Sales LLC, Integra LifeSciences Services (France) SAS, Integra LifeSciences Shared Services (Ireland) Limited, Integra LifeSciences Singapore Pte. Ltd., Integra LifeSciences Spain S.L., Integra LifeSciences Switzerland Sárl, Integra Luxtec Inc., Integra ME GmbH, Integra MicroFrance SAS, Integra NeuroSciences (International) Inc., Integra NeuroSciences Holdings (UK) Limited, Integra NeuroSciences Holdings B.V., Integra NeuroSciences Implants (France) SAS, Integra NeuroSciences Limited, Integra Neurosciences, Integra Neurosciences Pty Ltd. (AUS), Integra Neurosciences Pty Ltd. (NZ), Integra Receivables LLC, Integra Sales Inc., Integra Selector LLC, Integra Switzerland Holdings Sarl, Integra York PA Inc., IsoTis NV, IsoTis T.E. Facility B.V., J. Jamner Surgical Instruments Inc., Jarit GmbH, Kinetikos Medical, Koby Ventures II L.P. dba Metasurg, LXU Healthcare Inc. - Medical Specialty Products, MedEfficiency Inc., Medtronic Xomed Instrumentation SAS, Miltex, Minnesota Scientific Inc., Nantong Derma Medical Products Co. Ltd., Newdeal Inc., Newdeal SAS, Omni-Tract, Precise Dental Holding Corp., Precise Dental Internacional S.A. de C.V., Precise Dental Products Ltd., Precision Dental International Inc., Rebound Therapeutics, Rebound Therapeutics Corporation, Spembly Cryosurgery Limited, Spembly Medical Limited, TEI Biosciences (UK) Limited, TEI Biosciences Inc., TEI Biosciences Inc., TEI Medical Inc., TGX Medical Systems, TGX Medical Systems LLC, Tarsus Medical Inc., Tarsus Medical Inc., Tekmed Instruments S.p.A, Theken Disc, Theken Spine, and Therics.
Read More
How can I contact Integra LifeSciences?: Integra LifeSciences' mailing address is 311 ENTERPRISE DRIVE, PLAINSBORO NJ, 08536. The official website for the company is www.integralife.com. The life sciences company can be reached via phone at (609) 275-0500, via email at ir@integralife.com, or via fax at 609-750-4277.

This page (NASDAQ:IART) was last updated on 9/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial